

January 15, 2021

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549-3720

Attention: David Gessert

**Re: Athira Pharma, Inc.  
Draft Registration Statement on Form S-1 Submitted January 6, 2021  
Registration Statement on Form S-1 to be filed on January 19, 2021  
(File No. 333- )  
Acceleration Request  
Requested Date: Wednesday, January 20, 2021  
Requested Time: 4:30 P.M. Eastern Daylight Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Athira Pharma, Inc. (the “**Company**”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333- ) (the “**Registration Statement**”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Michael Nordtvedt at (206) 883-2524 or Bryan King at (206) 883-2535.

*[Signature page follows]*

---

Sincerely,

ATHIRA PHARMA, INC.

/s/ Leen Kawas

Leen Kawas  
*President and Chief Executive Officer*

Enclosures

cc: Glenna Mileson, Athira Pharma, Inc.  
Michael Nordtvedt, Wilson Sonsini Goodrich & Rosati P.C.  
Bryan D. King, Wilson Sonsini Goodrich & Rosati P.C.  
Charles S. Kim, Cooley LLP  
Alan D. Hambelton, Cooley LLP  
Oren Lang-Furr, Ernst & Young LLP